27806641|t|Empty Capsids and Macrophage Inhibition / Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice
27806641|a|Gene therapy has potential to treat rheumatic diseases; however, the presence of macrophages in the joint might hamper adeno-associated viral vector -mediated gene delivery. Here we demonstrate that in arthritic, but also in healthy, mice administration of agents that influence macrophage activity / number and/or addition of empty decoy capsids substantially improve the efficacy of recombinant adeno-associated viral vector 5 transgene expression in the joint. Pretreatment with triamcinolone or clodronate liposomes improved luciferase expression over a period of 4 weeks. Similar results were seen when empty decoy capsids were added to full genome containing capsids in a 5:1 ratio. In a study to assess the duration of expression as well as to investigate the combination of these two approaches, we observed a synergistic enhancement of gene expression, sustained for at least 12 weeks. The enhancement of gene expression was independent of the route of administration of triamcinolone (intra-articular or intramuscular). In healthy mice it was demonstrated that the combination improved expression of the transgene significantly, in a serotype independent manner. These data have implications for future applications of gene therapy to the joint and for other tissues with an abundance of macrophages.
27806641	0	5	Empty	T080	C1880497
27806641	6	13	Capsids	T017	C0006933
27806641	18	28	Macrophage	T025	C0024432
27806641	29	39	Inhibition	T052	C3463820
27806641	42	51	Depletion	T169	C0333668
27806641	52	60	Increase	T169	C0442805
27806641	61	65	rAAV	T121	C1520007
27806641	66	75	Transgene	T028	C0282641
27806641	76	86	Expression	T045	C0017262
27806641	90	96	Joints	T030	C0022417
27806641	105	112	Healthy	T080	C3898900
27806641	117	126	Arthritic	T047	C0003864
27806641	127	131	Mice	T015	C0025929
27806641	132	144	Gene therapy	T061	C0017296
27806641	149	158	potential	T080	C3245505
27806641	162	167	treat	T061	C0087111
27806641	168	186	rheumatic diseases	T047	C0035435
27806641	201	209	presence	T033	C0150312
27806641	213	224	macrophages	T025	C0024432
27806641	232	237	joint	T030	C0022417
27806641	251	273	adeno-associated viral	T005	C0001417
27806641	274	280	vector	T121	C1520007
27806641	291	304	gene delivery	T077	C1524066
27806641	334	343	arthritic	T047	C0003864
27806641	357	364	healthy	T080	C3898900
27806641	366	370	mice	T015	C0025929
27806641	371	395	administration of agents	T058	C2348003
27806641	401	410	influence	T077	C4054723
27806641	411	421	macrophage	T025	C0024432
27806641	422	430	activity	T052	C0441655
27806641	433	439	number	T081	C0237753
27806641	447	455	addition	T169	C1883712
27806641	459	464	empty	T080	C1880497
27806641	465	478	decoy capsids	T017	C0006933
27806641	493	500	improve	T033	C0184511
27806641	505	513	efficacy	T080	C1280519
27806641	517	528	recombinant	T001	C1514798
27806641	529	551	adeno-associated viral	T005	C0001417
27806641	552	558	vector	T121	C1520007
27806641	561	570	transgene	T028	C0282641
27806641	571	581	expression	T045	C0017262
27806641	589	594	joint	T030	C0022417
27806641	596	608	Pretreatment	T052	C3539076
27806641	614	627	triamcinolone	T109,T121	C0040864
27806641	631	641	clodronate	T109,T121	C0162357
27806641	642	651	liposomes	T109	C0023828
27806641	652	660	improved	T033	C0184511
27806641	661	671	luciferase	T116,T126,T130	C0024075
27806641	672	682	expression	T045	C0017262
27806641	690	696	period	T079	C1948053
27806641	702	707	weeks	T079	C0439230
27806641	709	716	Similar	T080	C2348205
27806641	717	724	results	T033	C0683954
27806641	740	745	empty	T080	C1880497
27806641	746	759	decoy capsids	T017	C0006933
27806641	765	770	added	T169	C1524062
27806641	774	778	full	T080	C0443225
27806641	779	785	genome	T028	C0017428
27806641	797	804	capsids	T017	C0006933
27806641	814	819	ratio	T081	C0456603
27806641	826	831	study	T062	C0008972
27806641	835	841	assess	T052	C1516048
27806641	846	854	duration	T079	C0449238
27806641	858	868	expression	T045	C0017262
27806641	883	894	investigate	T169	C1292732
27806641	899	910	combination	T080	C0205195
27806641	924	934	approaches	T169	C1292724
27806641	939	947	observed	T169	C1441672
27806641	950	961	synergistic	T080	C2986495
27806641	962	973	enhancement	T052	C2349975
27806641	977	992	gene expression	T045	C0017262
27806641	994	1003	sustained	T169	C0443318
27806641	1020	1025	weeks	T079	C0439230
27806641	1031	1042	enhancement	T052	C2349975
27806641	1046	1061	gene expression	T045	C0017262
27806641	1085	1108	route of administration	T169	C0013153
27806641	1112	1125	triamcinolone	T109,T121	C0040864
27806641	1127	1142	intra-articular	T082	C0442108
27806641	1146	1159	intramuscular	T082	C0442117
27806641	1165	1172	healthy	T080	C3898900
27806641	1173	1177	mice	T015	C0025929
27806641	1207	1218	combination	T080	C0205195
27806641	1219	1227	improved	T033	C0184511
27806641	1228	1238	expression	T045	C0017262
27806641	1246	1255	transgene	T028	C0282641
27806641	1276	1284	serotype	T170	C0449943
27806641	1311	1315	data	T078	C1511726
27806641	1361	1373	gene therapy	T061	C0017296
27806641	1381	1386	joint	T030	C0022417
27806641	1401	1408	tissues	T024	C0040300
27806641	1417	1426	abundance	T080	C2346714
27806641	1430	1441	macrophages	T025	C0024432